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Abstract. Phenothiazines have been used in many areas of
medicine, mainly in psychopharmacology. These compounds
are able to effectively inhibit dopamine, histamine, serotonin,
acetylcholine, and α-adrenergic receptors; thus, their effect
and side-effect profiles are extremely diverse. Besides their
antipsychotic activity, phenothiazines have a significant
antimicrobial effect as well, since they can enhance the
bactericidal function of macrophages and inhibit efflux pumps.
They are also able to eliminate bacterial resistance plasmids
and destroy bacteria by their membrane-destabilizing effect.
Their antiviral, antiprotozoal, antifungal, and antiprion
activities have also been described. Phenothiazines have also
been proven to destroy cancer cells and sensitize them to
chemotherapy. Anti-angiogenesis and anticancer stem cell
activities have also been reported, and they might be applied
as adjuvants in the treatment of infections and tumors in the
future. Finally, phenothiazines can also be effective in the
treatment of neurodegenerative diseases, such as Alzheimer’s
disease and Parkinson’s disease. 
Phenothiazines are unanimously one of the most versatile
compounds from the view of biological activity. Since their
discovery, new exploitable pharmacological properties have
emerged from time to time; thus, they have an important role
in many areas of medicine and beyond. This is why
phenothiazines are basic compounds in pharmacology. The
history of these compounds goes back to the second half of
the 19th century, when a German chemist, Heinrich August
Bernthsen began to study the structure of methylene blue,
which was first synthesized in 1876 by Heinrich Caro. In
1885, two years after Bernthsen first managed to produce
phenothiazine, he also succeeded in describing the structure
of methylene blue (1). At the same time, Paul Ehrlich began
to investigate the possible therapeutic use of methylene blue
in malaria infections, which he first published in 1891 (2).
Due to this, methylene blue was often prescribed for patients
with malaria in the subsequent period (3).
Research conducted in the 1930s and ‘40s proved the
potential wide use of phenothiazines. The insecticidal (4),
antihelmintic (5, 6), and antibacterial (7) effects of the
compound were detected; however, it was not widely used for
these purposes. In the 1940s, another novel phenothiazine
derivative, namely promethazine was brought to the forefront
of attention; it was investigated by Paul Charpentier at the
Rhone-Poulenc laboratory in Paris (8). It was shown that
promethazine had an antihistamine effect (9), which was later
used in the therapy of allergic diseases and in anesthesia (10,
11). A few years later in the same laboratory, chlorpromazine
was discovered, which has strong anxiolytic and antipsychotic
effect along with its antihistaminic effect (12). Psychiatry fully
exploited this feature in psychotic patients (13), which resulted
in the almost complete emptying of psychiatric hospitals in the
1950s. As a result, the discovery of chlorpromazine and the
beginning of its use as an antipsychotic are considered the
beginning of modern psychiatry and psychopharmacology.
Since then, several antipsychotic phenothiazine
compounds have been used in clinical practice, although
research conducted in the last couple of decades indicated
that phenothiazine compounds could have an important role
in other fields of medicine as well, such as in the treatment
of tumorous, infectious, or neurodegenerative diseases (3).
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Principal Compounds with Phenothiazine 
Skeleton and Their Structure
Phenothiazine. As has been described above, methylene blue
was the first compound synthesized with a phenothiazine
skeleton. Only afterwards was phenothiazine synthesized by
heating diphenylamine and sulfur by Bernthsen. Currently,
the reaction is mostly performed by the cyclization of 2-
substituted diphenyl sulfides (14) (Figure 1).
In general, compounds derived from the phenothiazine
skeleton are characteristic of an alkyl side chain attached to
a nitrogen in position 10, which is responsible for its specific
properties, whereas the substituent on the carbon atom at
position 2 has an impact on its efficacy. On carbon atom 2,
mainly highly electronegative lipophilic substituents, such as
halogens, give the highest efficacy, especially the
trifluoromethyl group. The action profile of the compound is
particularly influenced by the length of the alkyl side chain;
thus, for example, a three-carbon atom alkyl chain should be
present between the nitrogen at position 10 and the terminal
nitrogen of the phenothiazine skeleton in order to achieve an
antipsychotic effect, whilst in case of a carbon atom at
position 2, there is an antihistaminergic activity rather than
an antipsychotic effect (15). Efficacy increases if the
terminal amino group is substituted with piperazine, and also
if the hydrophobicity of the substituents is higher, due to
their penetration across the blood–brain barrier. 
Methylene blue. Methylene blue has the greatest chain-
breaking antioxidant activity of all the phenothiazine
compounds, which is due to the fact that a hydrogen atom can
easily leave the nitrogen atom in the reduced methylene blue
(leucomethylene blue), and the resulting free radical of
leucomethylene blue forms a particularly stable compound
with mesomerism, which is methylene blue itself.
Furthermore, the leucomethylene blue free radical can also act
as an electron donor (Figure 2). Due to these characteristics,
the compound has a remarkable antioxidant activity, which is
utilized in many areas (3). Moreover, it has an inhibitory effect
on nitric oxide synthase and guanylate cyclase (16).
Typical antipsychotics can be structurally grouped
according to the structure of the side chain connected to the
atom at position 10 (Table I). According to this, aliphatic,
piperidine and piperazine type compounds can be
distinguished (promethazine is not an antipsychotic, but it
also has an aliphatic side chain).
Promethazine. Among phenothiazines, the structure of
promethazine is most similar to that of histamine; thus, its
histamine antagonistic effect can be derived from it as it
inhibits histamine H1 receptors, and it also has an
anticholinergic and a mild anti-dopaminergic activity
(Figure 3) (17).
Chlorpromazine. The structure of chlorpromazine is most
similar to that of dopamine; therefore, it is able to
effectively inhibit dopamine receptors, and thus exert
antipsychotic effects (18). Nevertheless, it has anti-
serotoninergic, anti-muscarinic, antihistaminergic and α-
adrenergic receptor inhibitory activity as well (Figure 4).
N-Methyl-D-aspartate (NMDA) receptor inhibitory effects
have also been described at high concentrations of
chlorpromazine (19).
Levomepromazine. Levomepromazine is similar to
chlorpromazine in its structure and pharmacodynamics, but
considering its antipsychotic effect, levomepromazine is
approximately half as potent as chlorpromazine; nonetheless,
it causes fewer extrapyramidal side-effects (EPS) (Figure 4).
It has the most powerful sedative effect of all antipsychotics,
and it is widely used in palliative care for its powerful
analgesic, sedative and anti-emetic effects (20).
Thioridazine. The pharmacodynamics of thioridazine is similar
to that of chlorpromazine; however, its adverse effect profile is
different since thioridazine causes fewer EPS, and instead,
anticholinergic symptoms are predominant (Figure 4). 
Due to the anti-bacterial and antitumor effects of
thioridazine, it is still a focus of research. 
Trifluoperazine. Trifluoperazine has higher affinity towards
dopamine receptors and lower towards serotonin and adrenergic
receptors; thus, it is generally better tolerated by patients, but it
causes more EPS in the long term (Figure 4). In clinical
practice, it is mainly used in the therapy of schizophrenia and
in the treatment of anxious and agitated patients. Similarly to
thioridazine, it is frequently applied for research purposes (20).
Pharmacodynamics
Phenothiazine derivatives are often referred to as ‘dirty
drugs’ because they act on so many receptors. The
pharmacodynamic effects of phenothiazine derivatives that
are used in clinical practice, particularly for their
antipsychotic effect, are detailed in the following.
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Figure 1. The structure of phenothiazine.
Antidopaminergic effect. The most important feature of
phenothiazine derivatives with antipsychotic activity is that
they non-selectively inhibit all the five types of dopamine
receptors. Their most important effect is their D2 (and D3)
receptor-blocking activity, since it is correlated with the
antipsychotic effect of the molecule (21). The highest density
of D2 receptors in the brain is found in the striatum, nucleus
accumbens, ventral tegmental area, and substantia nigra, and
the therapeutic effect is due to the inhibition of D2 receptors
in neurons originating from the ventral tegmental area, and
projecting to the limbic system (mesolimbic dopaminergic
pathway). As a result, phenothiazine-based antipsychotics can
effectively reduce the positive symptoms of schizophrenia
(hallucinations, delusions, and disorganized speech and
behavior). Furthermore, dopamine receptor blockade of the
medullary chemoreceptive trigger zone also results in an
antiemetic effect. However, the adverse effects of the drug are
also due to inhibition of D2 receptors. The inhibition of the
dopaminergic nigro-striatal system leads to a wide variety of
EPS, such as akathisia, tardive dyskinesia, parkinsonism,
acute dystonic reactions, and other drug-induced dyskinesias
(tic, chorea, or athetosis). The anti-dopaminergic effect on the
tuberoinfundibular system causes hyperprolactinemia as a
result of the termination of tonic inhibition of lactotrophic
cells by dopamine. The D2 receptor blockade is proven to be
in the background of neuroleptic malignant syndrome
(hyperthermia, muscle rigidity, and autonomic dysregulation),
which is a potentially fatal adverse effect (22). 
Antihistaminergic effect. All phenothiazine derivatives used in
clinical practice have an antihistamine effect, among which
promethazine has the most significant one. It mainly involves
inhibition of H1 receptors, and plays a role in the alleviation of
allergic symptoms (17). In the nervous system, H1 receptors are
found mainly in the tuberomammillary nucleus. This area is
responsible for multiple tasks, among which regulation of the
sleep–wake cycle, appetite and body temperature are the most
essential. The inhibition of the histaminergic neurons in this
nucleus is responsible for the sedative effects of antihistamines
and antipsychotics, and for an increased appetite, moreover
subsequent hypothermia or hyperthermia may also develop
through the inhibition of body temperature regulation (23). 
Antiserotonergic effect. Phenothiazine antipsychotics have high
affinity for serotonin (5-hydroxytryptamine, 5-HT) receptors,
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Table I. Phenothiazine groups.
Derivatives with aliphatic side chains                          Chlorpromazine, promazine, triflupromazine, levomepromazine, (promethazine)
Piperidine derivatives                                                    Thioridazine, mesoridazine
Piperazine derivatives                                                    Fluphenazine, perphenazine, prochlorperazine, trifluoperazine
Figure 2. The structure and the redox cycle of methylene blue.
Figure 3. Structural similarities between promethazine, histamine and
dopamine, which explain the pharmacological properties of
promethazine and other phenothiazine derivatives. 
the most important of which is the inhibition of 5-HT1A, 5-
HT2A, and 5-HT2C receptors in achieving the antipsychotic
effect (24); however, it is crucial mainly in the case of atypical
antipsychotics. For phenothiazine antipsychotics, the inhibition
of serotonin receptors results in anxiolytic and antidepressant
activity, it reduces aggression and the risk of developing EPS,
but leads to weight gain, changes in blood pressure, and the
development of ejaculatory disorders (25).
Alpha-adrenergic receptor-blocking effect. Phenothiazine-
type antipsychotics can inhibit both α1 and α2 adrenergic
receptors. The inhibition of α1 receptors is mainly
responsible for the sympatholytic side-effects such as
hypotension, orthostatic hypotension, reflex tachycardia,
dizziness, myosis, and sexual dysfunction. The inhibition of
α2 receptors may have an antidepressant effect (25).
Anticholinergic effect. Phenothiazine antipsychotics have
special affinity for M1 and M2 muscarinic acetylcholine
receptors. The inhibition of M1 receptors can be related to
the blocking activity of the autonomic ganglia, which results
in autonomic symptoms, such as dry mouth, constipation,
urinary retention, dry and warm skin, nausea, mydriasis,
closed-angle glaucoma, nasal congestion, priapism, and
orthostatic hypotension. Phenothiazines can effectively
reduce sea sickness because of their central antimuscarinic
effect (22).
Antiglutaminergic effect. It has recently been reported that at
low concentration, phenothiazine derivatives stimulate
glutaminergic transmission on NMDA receptors, and at high
concentration, they inhibit it (19). 
Antimicrobial Effect
Antibacterial effect. The antimicrobial effect of
phenothiazines has been the subject of numerous studies to
date, which supports the idea that phenothiazine therapy can
be an effective option in the treatment of certain bacterial
infections. Such an effect of phenothiazine derivatives can
manifest as a direct antibacterial effect and also as an effect
reducing or inhibiting antibiotic resistance, in the background
of which several possible mechanisms have already been
described. Among these mechanisms, one of the most
important is the inhibition of bacterial multidrug resistance
(MDR) efflux pumps. Since bacterial MDR proteins prevent
antibiotics from achieving an appropriate bactericidal
concentration in the cytoplasm, they are largely responsible
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Figure 4. The structure of chlorpromazine, levomepromazine, thioridazine and trifluoperazine.
for the development of resistance to antibiotics, and by
inhibiting these pumps, bacteria can be re-sensitized to the
corresponding antibiotics. Phenothiazines inhibit the binding
of calcium to calcium-dependent proteins, such as
calmodulin, and they can inhibit MDR efflux pumps using
energy derived either from ATP hydrolysis or proton motive
force. As a result, MDR pumps are inhibited, and the
antibiotic drug is able to accumulate in the cytoplasm of the
bacterium (26). Besides the efflux pump inhibitory effect,
phenothiazine can also inhibit bacterial replication as it
inhibits DNA-based processes and replication by intercalating
DNA bases. It may be potentially of major importance in case
of infections caused by multi-resistant bacteria, such as
multidrug resistant Mycobacterium tuberculosis, methicillin
resistant Staphylococcus aureus, and other infections caused
by Gram-positive pathogens, but it also appears to be
essential during therapy of infections caused by some Gram-
negative rods, such as Shigella, Salmonella, and Escherichia
coli (26-28). The antibacterial effect of phenothiazines, such
as chlorpromazine and thioridazine, was achieved at in vitro
concentrations (25 μg/ml) highly exceeding the clinically
relevant plasma concentration (0.5 μg/ml); however, it has
been shown that phenothiazines are able to reach up to 100-
fold concentration in macrophages and cause destruction of
phagocytosed bacteria. Thus, a therapeutic effect can be
achieved at a plasma concentration which is lower than that
used in antipsychotic therapy (29). 
Another important feature of phenothiazines is their
plasmid-eliminating effect. The research about this effect has
been mainly on promethazine, which clearly demonstrated
its ability to inhibit the replication of bacterial resistance
plasmid (R-factor), thereby reducing or even eliminating
resistance to antibiotics. Inhibition of the replication of the
R-factor, i.e. the polyresistance factor, occurs because
promethazine binds to and complexes with the guanine- and
cytosine-rich regions of plasmid DNA (30), thus inhibiting
replication. However, inhibition of plasmid conjugation by
preventing formation of sex pili is also a possible mechanism
(31). Moreover, inhibition of other plasmid-related functions
was also observed in the presence of promethazine, which is
due to the fact that it is also able to inhibit plasmids with
other functions, such as the virulence plasmid, in addition to
the R-plasmid. Taking advantage of this feature, a synergistic
effect has been described while using promethazine in
combination with gentamicin for the treatment of recurrent
urogenital infections caused by E. coli, and the therapy was
also successful in cases with gentamicin-resistant pathogen
(32). Besides the anti-plasmid mechanism, the inhibition of
bacterial adhesion to the urothelium may also be responsible
for the above-described findings. Furthermore, antibacterial
activity of phenothiazines can be related to their membrane-
destabilizing effect, since it has been observed that
phenothiazine compounds increase the membrane
permeability of certain bacteria, and as a result, it is easier
for antibiotics to penetrate through the membrane (33).
Nevertheless, as a result of the disturbed ion gradient, several
intracellular processes may be disturbed, and the motility of
the bacteria may also be inhibited (34). 
Antiprotozoal effect. Ehrlich described the antimalarial effect
of methylene blue as early as in the 1910s; however, due to
the spread of chloroquine-resistant Plasmodium strains,
phenothiazines may regain their important role in the therapy
of patients with malaria. Several studies have already
confirmed the antimalarial effect of chlorpromazine both in
vitro and in vivo; direct bactericidal effect and ability to inhibit
the resistance to chloroquine have also been described (35).
Most recently, it was detected that chlorpromazine is capable
of effectively destroying Naegleria fowleri both in vitro and
in vivo. The prognosis of patients with meningoencephalitis
caused by N. fowleri is very poor, with a mortality of 95%
even with the administration of adequate therapy. At present,
amphotericin B is considered to be an adequate therapy for
naegleriasis; however, it has been revealed that the survival
rates were 35% higher in mice infected with Naegleria and
then treated with chlorpromazine than in the those treated with
amphotericin B (36). 
Antiviral effect. There have also been many achievements
regarding the antiviral effect of phenothiazines. Mainly the
antiviral effect of chlorpromazine has been studied so far, in
the background of which there might be several mechanisms,
for example, inhibiting the binding of the virus to its receptor
on the plasma membrane, blocking endocytosis of the virus
by inhibiting the required calcium-dependent processes, and
inhibiting the DNA replication by intercalating DNA bases
(27). Most of the published studies were on the antiviral
activity of chlorpromazine in vitro. These articles reported
that chlorpromazine is able to inhibit the replication of the
genetic material in hepatitis B virus (37), SV40 (38), and
arenavirus (39); viral budding in measles (40), Sindbis and
vesicular stomatitis virus (41), and infection with HIV (42),
human herpes virus (43), and John Cunningham viruses (44).
Although these effects were achieved at clinically-irrelevant
concentrations, the observation that phenothiazines have a
potential antiviral effect provided the idea for developing
several phenothiazine derivatives that are able to exert
antiviral effect at lower plasma concentrations. 
Antifungal effect. It has already been reported that
phenothiazine compounds are able to inhibit the growth of
certain fungi (Candida species, Cryptococcus neoformans)
(45). Besides antifungal activity, synergistic effects have
been described when administered in combination with
certain antifungal agents, such as amphotericin B or
ketoconazole (46). The mechanism behind the fungicidal
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effect of phenothiazines is not yet fully understood, but is
probably due to the membrane-destabilizing effect and the
inhibition of calcium–calmodulin system, which have also
been observed in bacteria (47). In recent years, an antifungal
effect against filamentous fungi has also been reported,
namely in case of Aspergillus, Scedosporium, and
Zygomycetes species (48). In the therapy of Zygomycetes-
induced rhinocerebral zygomycosis, the synergistic effect of
trifluoperazine co-administered with amphotericin B seems
to be promising (49). 
Anti-prion activity. Until now no potent medication which
could prolong patient survival to some extent has been found
against the protein-based infectious agent of Creutzfeld–
Jakob disease, Gerstmann–Sträussler–Scheinker syndrome,
and Kuru. However, it has been proven in infected mouse
neuroblastoma cell cultures that chlorpromazine is able to
inhibit the formation of aberrant prion proteins together with
another heterocyclic compound, which is quinacrine (50).
The anti-prion effect of these two compounds observed in
cell cultures has not been evident in vivo, which may be due
to the fact that the drug was unable to reach appropriate
concentrations in the brain (51). Further studies and research
are needed to fully exploit the potentials of these two
compounds.
Antitumor Effect
Due to their wide biological activity, phenothiazines also
have an important role in cancer research. They can exert
antitumor activity through several mechanisms, the most
important of which are the processes inducing apoptosis,
such as the inhibition of DNA-repair mechanisms and signal
transduction pathways, but their direct DNA-damaging and
membrane-destabilizing effects are also outstanding. It is
also important to emphasize the ability of phenothiazines in
inhibiting MDR tumor resistance, and their anti-angiogenesis
effect; however, they are also able to exert antitumor activity
through several further processes.
Apoptosis-inducing effect. The importance of inhibiting
DNA repair mechanisms lies in the fact that if DNA
damage remains intact at transition points of the cell cycle,
the appropriate checkpoint proteins, such as p53, initiate
the internal death signal, thereby inducing apoptosis. DNA-
dependent protein kinase, which is a serine/threonine
kinase, plays an important role in repairing damage to the
DNA chain. Phenothiazines have been shown to be able to
inhibit the DNA-dependent protein kinase in vitro (52), as
a result of which the effectivity of DNA repair is lower;
however, they are also purported to interfere with further
DNA-repair processes (53). This assumption is based on
the observation that phenothiazines reduce endonuclease
activity in human fibroblast cells, which plays an important
role in the DNA-repair mechanisms (54). However,
phenothiazines can exert an effect on checkpoint proteins
not only directly but indirectly as well. Translationally
controlled tumor protein (TCTP) is an important regulatory
protein in the cell cycle; it stimulates ubiquitination, and
thus the degradation of p53 protein. However, it has been
shown that thioridazine is able to inhibit TCTP and increase
the expression of p53 protein, and thus its activity in
inducing apoptosis (55). It may have practical importance,
for example, in case of tumors with high TCTP expression
(56). Furthermore, thioridazine is able to block the so-
called Tousled-like kinases, which are responsible for the
chromatin rearrangement in the S-phase of the cell cycle,
and the inhibition of which consequently leads to genomic
instability and apoptosis (57). Similar processes may exist
in the background of the observations that thioridazine
reduces the expression of cyclin D1 and cyclin-dependent
kinase 4 (CDK4), and increases the expression of CDK
inhibitor proteins, such as p16 and p27. Cyclin D1 and
CDK4 play an important role in the G1/S transition, while
p16 and p27 inhibit G1/S and G2/M transitions. It has been
shown that thioridazine reduces the expression of various
anti-apoptotic and antiproliferative proteins, such as B-cell
lymphoma-2 (BCL2), survivin, and cellular myelo-
cytomatosis oncogene (c-MYC) (58). It was mentioned
earlier that phenothiazines inhibit the binding of calcium to
many calcium-dependent enzymes, such as calmodulin. As
a result, many calcium-mediated signal transduction
pathways can be disturbed, which may result in apoptosis
and the inhibition of proliferation (59). The blockade of the
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)
pathway has the same consequence, and it can be
effectively inhibited by thioridazine; the resulting cytotoxic
effect has been demonstrated in cervical and endometrial
tumor cells (60). It has also been shown that tumor cells
having a mutation in their B-type rapidly accelerated
fibrosarcoma (BRAF) gene at codon 600 exhibit increased
sensitive to the antiproliferative effect of phenothiazines,
and this phenomenon has been confirmed in melanoma
cells in vitro (61). Furthermore, it is also likely that these
apoptosis-inducing processes could be even more effective
if supplemented by radiotherapy (62).
Some recent studies have also confirmed that the use of
phenothiazines leads to apoptosis and cell death. Some
examples of these are the following: the apoptosis-inducing
effect of phenothiazines described above has been
confirmed by different studies on lymphatic and leukemia
cells. In these experiments, thioridazine was the main focus
of interest; however, trifluoperazine and chlorpromazine
presented similar antitumor activity at clinically relevant
concentrations. It is important to note that the induction of
apoptosis in leukemia cells was achieved while healthy
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lymphocytes remained intact; therefore phenothiazines also
show some degree of selective toxicity (63). Similar
antitumor effects have been demonstrated in MDR
melanoma cells in vitro, as well as in vivo after injecting
these cells into mice. In this analysis, the apoptosis-
inhibiting effect of thioridazine was clearly observed in
vitro; while in vivo, studying the number of tumor foci in
the mouse lungs and their survival rates, thioridazine was
shown to be effective against this tumor type (64). During
in vitro experiments, in which MDR mouse T-lymphoma
cells were treated with thioridazine, along with the
apoptosis-inducing effect, the agent was also effective in
the inhibition of P-glycoprotein (ABCB1 protein), which is
the most studied MDR ATP-binding cassette transporter of
tumor cells (65). It has been described that a newly
synthesized 2,7-diazaphenothiazine derivative, 10-[4-(4-
methylpiperazin-1-yl)but-2-ynyl]-2,7-diazaphenothiazine,
exerted pronounced anticancer activity against T47D
human ductal breast epithelial tumor cells. Furthermore,
against T47D cells this 2,7-diazaphenothiazine derivative
had stronger anticancer properties than cisplatin. According
to the analysis of the BLC2/BCL2-associated X protein
(BAX) gene-expression ratio in T47D cells mitochondrial
apoptosis was induced after 24 hours of treatment in the
presence of the derivative (66). In addition, photodynamic
therapy is a method for inducing tissue damage with light
irradiation of a drug selectively retained in malignant
tissue, for example in case of the photosensitizing drug
methylene blue (67). 
Inhibition of efflux pumps. Efflux pumps play an important
role in the chemotherapy resistance of cancer cells as well
as in the antibiotic resistance mechanisms of bacteria.
There are three main types of MDR proteins in humans,
out of which the most important role is played by ABCB1,
previously called MDR1 or P-glycoprotein, and ABCC1
and ABCC2 from the ABCC family, also known as MRP1
and MRP2 (68). Overexpression of these proteins may be
observed in chemotherapy-resistant tumor cells, and as in
case of bacteria, phenothiazines also have a beneficial
effect as efflux pump inhibitors. It has also been confirmed
by various experiments where, for example, thioridazine
made resistant sarcoma sensitive to doxorubicin again by
the inhibition of P-glycoprotein (69). Multidrug-resistant
KBV20C human oral squamous carcinoma can be adapted
to eribulin at 500-fold higher than that used to treat their
drug sensitive parental counterparts indicating that eribulin
may be effectively pumped out by ABCB1. Thioridazine
is able to sensitize eribulin-resistant KBV20C cells,
moreover, the combined effect of eribulin and thioridazine
resulted in G2 arrest (70). In another study, ABCB1 of
MDR mouse T-lymphoma cells was also inhibited by
thioridazine (71).
These observations raise the possibility of using
resistance-modifying compounds in the future as adjuvants
to chemotherapy, for example, efflux pump inhibiting
phenothiazines. The dose of chemotherapeutic agents could
be reduced as well as their adverse effects, whereas the
efficacy of the therapy could be increased since the
chemotherapeutic agents themselves also induce the
excessive expression of MDR efflux pumps of tumor cells.
We should bear in mind, though, that several further
investigations are required before these compounds can be
used in clinical practice as MDR proteins are not only found
in tumor cells, but also play an essential role in the normal
functioning of the blood–brain barrier, the kidneys, and the
liver. The inhibition of these physiological proteins involves
serious potential side-effects, especially if administered in
combination with chemotherapeutics. These potentially
adverse effects could be eliminated by using tumor cell-
specific efflux pump inhibitors; however, this option is still
to be investigated (62).
Inhibition of angiogenesis. Among phenothiazines,
thioridazine can also block the angiogenesis-stimulating effect
of tumors. Tumors need increased blood supply for their
intense metabolism, which they achieve by secreting vascular
endothelial growth factor (VEGF) and similar substances.
These substances exert an effect on the endothelial cells,
which results in small vessels entering the tumor. The
inhibition of these substances and the associated signal
pathways may play an important role in the inhibition of
tumor growth, especially in the more vascularized tumors. In
vivo experiments in mice have shown that the expression of
VEGF and hypoxia-inducible factor 1α (HIF1α) as well as
phosphorylation of VEGF receptor 2 are decreased in ovarian
tumors. Antibodies to VEGF have been shown to be effective
in the treatment of certain tumors; thus, it is suspected that this
property of phenothiazine derivatives may be utilized during
the therapy of the disease in the future (58).
Anticancer stem cell activity. Further studies with thioridazine
have also revealed that this compound is able to selectively
inhibit cancer stem cells (CSC) without inhibiting somatic
stem cells. A possible mechanism behind the anti-CSC effect
could be that thioridazine antagonizes dopamine receptors
that are expressed on CSCs (72). Similar observations have
been made in the case of glioblastoma stem cells, since
thioridazine is able to induce autophagy and selectively
destroy glioblastoma stem cells, and thus the glioblastoma
itself. This activity is exerted without affecting healthy
neurons and glial cells (73). It has also been shown that
thioridazine can suppress the proliferation and invasion of
colon CSCs and thioridazine can interfere with mitochondrial
membrane potential and can up-regulate the relative
expression of proapoptotic genes BAX and caspase-3 (74).
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Potential clinical use in oncology. In the light of the above
results, it can be concluded that phenothiazines and similar
compounds are likely to play an important role in the
treatment of oncology patients. Currently, the most
frequently used chemotherapeutic agents in tumor therapy
are not sufficiently selective; therefore, they not only
damage cancer cells, but also harm other healthy tissues
and cells, resulting in various side-effects. Serious efforts
have been made for a long time to develop even more
selective therapeutic tools to fight cancer. However, this
selectivity can be achieved by adding adjuvant compounds
which sensitize cancer cells to currently used
chemotherapeutics and radiotherapy. Thus, current therapies
can be more effective and selective, and the side-effects of
these chemotherapeutics can be eliminated, since using a
suitable adjuvant could reduce their dosage while achieving
the same effect. In addition, other pharmacological effects
of phenothiazines could also be used in the treatment of
patients with cancer. Currently, the most uncomfortable
side-effects of chemotherapeutics are nausea and vomiting,
which might be alleviated effectively by use of
phenothiazines. Phenothiazines may also be useful in the
palliative therapy of patients with cancer, for example, as
analgesics, and they may also play a role in the
psychological treatment of these patients (62).
Potential Role in the Treatment of 
Neurodegenerative Diseases 
As early as in 1992, research was conducted in mouse models
to reduce post-ischemic brain damage with phenothiazine pre-
treatment. This observation has been attributed to the redox
properties of phenothiazine, since it has been shown to inhibit
lipid peroxidation and to have cytoprotective effects on
neurons. Research was started in this context in the 2000s, but
as a result of the theories on the pathomechanism of
neurodegeneration. It was observed that oxidative stress caused
by reactive oxygen species played an important role in
neurodegeneration. Since phenothiazine and methylene blue
are among the most potent antioxidant compounds, it is evident
that they may have role in the treatment of neurodegenerative
processes. For example, phenothiazine and methylene blue
have been observed to be able to prevent dopaminergic neuro-
degeneration in Caenorhabditis elegans models of Parkinson’s
disease (75). There are ongoing studies related to the possible
treatment of Alzheimer’s disease with phenothiazines,
especially with methylene blue. Several theories have been
made to explain the pathomechanism of Alzheimer’s disease,
according to which the main triggers are abnormal aggregation
and plaque-like deposition of β-amyloid proteins, leading to
oxidative stress and abnormal phosphorylation and intracellular
aggregation of tau proteins, which make up the so-called
neurofibrillary bundles. Methylene blue is able to intervene in
these pathological processes at several points. Along with the
effect of reducing oxidative stress, methylene blue has also
been shown to effectively inhibit pathological phosphorylation
and aggregation of tau proteins in mouse models as well as
the up-regulation of protein degradation systems (proteasome
and autophagy). However, this agent was effective only
during prophylactic treatment, and did not exert its effect in
cases that had already developed (76). Furthermore, it is also
suspected that methylene blue can interfere with β-amyloid
misfolding and consequent extracellular aggregation, which
reflects the aforementioned anti-prion activity of the agent
as β-amyloid behaves similarly to prion proteins. Methylene
blue has also been proven in vitro to reduce oligomerization
of β-amyloids and to stimulate their fibrillization, resulting
in a less toxic structure (77). Methylene blue is an
antioxidant, since the molecule is able to bind reactive
oxygen species and to stabilize changes in the proteins of the
mitochondrial respiratory chain by redox cycling between
complexes I and IV (3).
Concluding Remarks
The diverse biological and pharmacological properties of
phenothiazines have been known since a long time, and they
are widely exploited especially in the field of psychiatry.
However, recent research has shown that these compounds may
have an important role in many other areas of medicine in the
future. 
The spread of antibiotic resistance is increasingly
challenging in the treatment of infectious diseases.
Phenothiazines, either alone or in combination with antibiotics,
may be promising alternatives to overcoming antibiotic
resistance, since they are able to interfere with the resistance
mechanisms and other cellular functions at several points. 
It has also been proven that phenothiazines are able to
eliminate cancer cells and sensitize them for chemotherapy by
multiple mechanisms; thus, it is believed that these compounds
will also be used as adjuvants in oncology in the near future. 
Finally, there is a promising perspective in the use of
phenothiazines during the treatment of neurodegenerative
diseases which currently have poor prognosis, such as
Alzheimer’s disease and Parkinson’s disease. 
To sum up, a new Renaissance may soon arrive for this
overlooked group of compounds according to recent
scientific research.
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